Etelcacetide

Short Description:

API’s Name CAS No. US DMF Patent Expiry Date (US) Current Status
Etelcacetide 1262780-97-1 Oct, 2026  Feb.7, 2031 estimated PV Completion – Apr, 2026

 

[Indication]

It is a calcimimetic agent indicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.


Product Detail

Product Tags


  • Previous:
  • Next:

  • Write your message here and send it to us